Asterias Announces Two Significant Developments for Spinal Cord Injury Program

Posted byclientekdevPosted instem cell research

https://globenewswire.com/news-release/2017/10/02/1138619/0/en/Asterias-Announces-Two-Significant-Developments-for-Spinal-Cord-Injury-Program.html

FREMONT, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today announced new 12-month data from the first efficacy cohort in the company’s ongoing Phase 1/2a SCiStar study designated to evaluate safety and efficacy of AST-OPC1…